|
US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
|
EP0773952B1
(de)
*
|
1994-07-20 |
2003-11-12 |
The General Hospital Corporation |
Interaktions-fullensysteme zum nachweis von protein-interaktionen
|
|
EP0830459B1
(de)
*
|
1995-04-11 |
2007-01-24 |
The General Hospital Corporation |
Reverse "two-hybrid"-systeme
|
|
EP1241265A3
(de)
*
|
1996-04-26 |
2004-02-18 |
Massachusetts Institute Of Technology |
Screening-Verfahren für kleine Liganden
|
|
EP0907750B1
(de)
*
|
1996-04-26 |
2002-09-18 |
Massachusetts Institute Of Technology |
Drei hybriden screening test
|
|
US5776689A
(en)
*
|
1996-07-19 |
1998-07-07 |
The Regents Of The University Of California |
Protein recruitment system
|
|
US5807708A
(en)
*
|
1996-07-30 |
1998-09-15 |
Millennium Pharmaceuticals, Inc. |
Conservin nucleic acid molecules and compositions
|
|
US5846722A
(en)
*
|
1996-10-16 |
1998-12-08 |
Terrapin Technologies, Inc. |
System to detect small molecule/peptide interaction
|
|
WO1998046796A1
(en)
*
|
1997-04-11 |
1998-10-22 |
The Regents Of The University Of California |
A method of screening nucleotide sequences to identify disruptors or effectors of biological processes or pathways
|
|
AU3587599A
(en)
*
|
1997-11-28 |
1999-06-16 |
Invitrogen Corporation |
Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
|
|
EP1035207A1
(de)
*
|
1999-03-09 |
2000-09-13 |
MultiGene Biotech GmbH |
cDNA Moleküle der Mitglieder der Genfamilie, die für menschliche Fettsäuredesaturasen kodieren, und deren Verwendung in Diagnostik und Therapie
|
|
AU780061B2
(en)
|
1999-04-12 |
2005-02-24 |
Agensys, Inc. |
Transmembrane protein expressed in prostate and other cancers
|
|
EP1792989A1
(de)
|
1999-04-12 |
2007-06-06 |
Agensys, Inc. |
13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
|
|
US20060073150A1
(en)
|
2001-09-06 |
2006-04-06 |
Mary Faris |
Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
|
|
AU6054900A
(en)
*
|
1999-06-26 |
2001-01-31 |
Odyssey Pharmaceuticals, Inc. |
An in vivo library-versus-library selection of optimized protein-protein interactions
|
|
JP4373637B2
(ja)
|
1999-08-12 |
2009-11-25 |
アジェンシス,インコーポレイテッド |
ヒト前立腺癌において発現されるc型レクチン膜貫通抗原およびその使用
|
|
CA2385032C
(en)
|
1999-10-05 |
2013-12-10 |
Agensys, Inc. |
G protein-coupled receptor up-regulated in prostate cancer and uses thereof
|
|
US6893818B1
(en)
*
|
1999-10-28 |
2005-05-17 |
Agensys, Inc. |
Gene upregulated in cancers of the prostate
|
|
US20030211495A1
(en)
*
|
2000-03-08 |
2003-11-13 |
Richard Hopkins |
Reverse n-hybrid screening method
|
|
AU2002218786A1
(en)
|
2000-07-12 |
2002-01-21 |
Agensys, Inc. |
Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
|
|
ATE403716T1
(de)
|
2000-08-28 |
2008-08-15 |
Agensys Inc |
Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
|
|
WO2002022685A2
(en)
*
|
2000-09-11 |
2002-03-21 |
Kufe Donald W |
Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
|
|
AU9630501A
(en)
|
2000-09-26 |
2002-04-08 |
Univ Duke |
Rna aptamers and methods for identifying the same
|
|
WO2002051438A2
(en)
|
2000-12-22 |
2002-07-04 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
|
EP1958642A1
(de)
*
|
2000-12-22 |
2008-08-20 |
Dana-Farber Cancer Institute |
Regulierung des Zellwachstums durch MUC1
|
|
US20030165873A1
(en)
|
2001-03-02 |
2003-09-04 |
Come Jon H. |
Three hybrid assay system
|
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
|
WO2002083921A2
(en)
|
2001-04-10 |
2002-10-24 |
Agensys, Inc. |
Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
|
|
SG2011071982A
(en)
*
|
2001-05-25 |
2016-09-29 |
Univ Duke |
Modulators of pharmacological agents
|
|
US20040049024A1
(en)
*
|
2001-12-07 |
2004-03-11 |
Geoff Clark |
Compositions and methods related to the minn1 tumor suppressor gene and protein
|
|
US20040086945A1
(en)
*
|
2002-06-03 |
2004-05-06 |
The Procter & Gamble Company |
Hairless protein-interacting partner complexes and methods thereto
|
|
AU2003280420A1
(en)
*
|
2002-06-26 |
2004-01-19 |
Yale University |
Modulators and modulation of the interacton between rgm and neogenin
|
|
US20040081653A1
(en)
|
2002-08-16 |
2004-04-29 |
Raitano Arthur B. |
Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
|
|
US20060099713A1
(en)
*
|
2002-10-01 |
2006-05-11 |
Buck Institute |
Targeted-assisted iterative screening (tais):a novel screening format for large molecular repertoires
|
|
CA2515699C
(en)
|
2003-02-10 |
2015-01-27 |
Aya Jakobovits |
Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
|
|
WO2004092339A2
(en)
*
|
2003-04-11 |
2004-10-28 |
Ilex Products, Inc. |
Modulation of muc1 mediated signal transduction
|
|
NZ572940A
(en)
|
2003-05-30 |
2010-04-30 |
Agensys Inc |
Prostate stem cell antigen (PSCA) variants and subsequences thereof
|
|
GB0315248D0
(en)
*
|
2003-06-30 |
2003-08-06 |
Hoffmann La Roche |
HCV regulated protein expression
|
|
US8129506B2
(en)
|
2003-10-24 |
2012-03-06 |
Genzyme Corporation |
Modulation of the interaction of MUC1 with MUC1 ligands
|
|
EP1533619B1
(de)
|
2003-11-20 |
2009-04-29 |
F. Hoffmann-Roche AG |
Spezifische Marker für Stoffwechselssyndrome
|
|
CA2556729A1
(en)
*
|
2004-02-23 |
2005-09-09 |
Genzyme Corporation |
Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
|
|
WO2005106042A2
(en)
*
|
2004-04-22 |
2005-11-10 |
Regado Biosciences, Inc. |
Improved modulators of coagulation factors
|
|
JP4651663B2
(ja)
|
2004-05-28 |
2011-03-16 |
アジェンシス,インコーポレイテッド |
Pscaタンパク質に結合する抗体および関連分子
|
|
US8034553B2
(en)
|
2004-06-24 |
2011-10-11 |
Kimberly-Clark Worldwide, Inc. |
Biomarkers for wound healing
|
|
EP2444099A1
(de)
|
2005-03-31 |
2012-04-25 |
Agensys, Inc. |
An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle
|
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
US9243243B2
(en)
|
2006-08-31 |
2016-01-26 |
Nexigen Gmbh |
Means and methods for detecting protein-peptide interactions
|
|
EP1927364A1
(de)
|
2006-12-01 |
2008-06-04 |
Ecole Normale Superieure De Lyon |
Polypetitde mit modulatorischer Wirkung auf Zellen
|
|
US7871784B2
(en)
*
|
2007-02-02 |
2011-01-18 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
|
|
US7972870B2
(en)
|
2007-02-02 |
2011-07-05 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
|
|
EP2034020A1
(de)
*
|
2007-08-30 |
2009-03-11 |
Procomcure Biotech GmbH |
Verfahren zur Herstellung eines modifizierten Peptids
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
EP2101173A1
(de)
*
|
2008-03-14 |
2009-09-16 |
Vivalis |
In-vitro-Verfahren zur Bestimmung, ob ein gegen ein Zielprotein aktiver Arzneimittelkandidat aktiv gegen eine Variante des besagten Proteins ist
|
|
US20110064202A1
(en)
*
|
2008-05-15 |
2011-03-17 |
Koninklijke Philips Electronics N.V. |
Method and system for generating an x-ray beam
|
|
US8796415B2
(en)
|
2009-10-22 |
2014-08-05 |
Centre National De La Recherche Scientifique |
Inhibitors of guanine exchange factors and their use as anticancer drugs
|
|
BR112012013734A2
(pt)
|
2009-12-08 |
2017-01-10 |
Abbott Gmbh & Co Kg |
anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
|
|
WO2011083147A1
(en)
|
2010-01-08 |
2011-07-14 |
Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh |
Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen
|
|
US20130116304A1
(en)
|
2010-04-19 |
2013-05-09 |
Ernst R. Werner |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
|
RS57603B1
(sr)
|
2012-01-27 |
2018-11-30 |
Abbvie Deutschland |
Sastav i metod za dijagnozu i tretiranje bolesti povezanih sa degeneracijom neurita
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
CN116869964B
(zh)
|
2014-12-24 |
2024-10-18 |
耐克西缪恩有限公司 |
用于免疫疗法的纳米颗粒组合物和方法
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
EP3377080B1
(de)
|
2015-11-19 |
2024-02-14 |
Asclepix Therapeutics, LLC |
Peptide mit anti-angiogenen, anti-lymphangiogenen und anti-ödematösen eigenschaften und nanopartikelformulierungen
|
|
CN108883180B
(zh)
|
2016-02-05 |
2023-07-07 |
奥里尼斯生物科学私人有限公司 |
Clec9a结合剂及其用途
|
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
|
CA3023883A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
EP3455245A2
(de)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutisches targeting von nichtzellulären strukturen
|
|
SG10202103032QA
(en)
|
2016-10-04 |
2021-05-28 |
Asclepix Therapeutics Inc |
Compounds and methods for activating tie2 signaling
|
|
ES2917000T3
(es)
|
2016-10-24 |
2022-07-06 |
Orionis Biosciences BV |
Interferón-gamma mutante diana y usos del mismo
|
|
MX2019009255A
(es)
|
2017-02-06 |
2019-11-05 |
Orionis Biosciences Nv |
Proteínas quiméricas dirigidas y sus usos.
|
|
US10906985B2
(en)
|
2017-02-06 |
2021-02-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
WO2018146074A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
US11674959B2
(en)
|
2017-08-03 |
2023-06-13 |
The Johns Hopkins University |
Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
|
|
US12059476B2
(en)
|
2017-10-10 |
2024-08-13 |
The Johns Hopkins University |
Biodegradable biomimetic particles
|
|
GB2584211B
(en)
|
2017-11-16 |
2023-05-24 |
Synthex Inc |
Selective modulation of protein-protein interactions
|
|
WO2019148089A1
(en)
|
2018-01-26 |
2019-08-01 |
Orionis Biosciences Inc. |
Xcr1 binding agents and uses thereof
|
|
KR102877915B1
(ko)
|
2018-02-05 |
2025-10-29 |
오리오니스 바이오사이언시즈 인코포레이티드 |
섬유아세포 결합제 및 이의 용도
|
|
CA3118892A1
(en)
|
2018-11-08 |
2020-05-14 |
Orionis Biosciences, Inc. |
Modulation of dendritic cell lineages
|
|
CA3129317A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
MA54955A
(fr)
|
2019-02-15 |
2021-12-22 |
Integral Molecular Inc |
Anticorps anti-claudine 6 et leurs utilisations
|
|
WO2020198665A1
(en)
|
2019-03-28 |
2020-10-01 |
Orionis Biosciences, Inc. |
Fibroblast activation protein binding agents and use thereof
|
|
JP7773376B2
(ja)
|
2019-05-15 |
2025-11-19 |
シンセックス, インコーポレイテッド |
タンパク質の選択的分解
|
|
EP4069731A4
(de)
|
2019-12-03 |
2024-05-29 |
Alamar Biosciences, Inc. |
Nukleinsäure-gekoppelter immun-sandwich-assay (nulisa)
|
|
GB202004514D0
(en)
|
2020-03-27 |
2020-05-13 |
Inst De Medicina Molecular Joaeo Lobo Antunes |
Treatment of Immunosuppressive Cancer
|
|
GB202009710D0
(en)
*
|
2020-06-25 |
2020-08-12 |
Univ Bath |
Cross-linking methods
|
|
WO2022081804A1
(en)
|
2020-10-14 |
2022-04-21 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2023019171A1
(en)
|
2021-08-10 |
2023-02-16 |
Viridian Therapeutics, Inc. |
Compositions, doses, and methods for treatment of thyroid eye disease
|
|
US20250304677A1
(en)
|
2022-07-04 |
2025-10-02 |
Vib Vzw |
Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
|
|
EP4598635A2
(de)
|
2022-10-06 |
2025-08-13 |
Bicara Therapeutics Inc. |
Multispezifische proteine und zugehörige verfahren
|
|
EP4626933A1
(de)
|
2022-11-30 |
2025-10-08 |
Integral Molecular, Inc. |
Gegen claudin 6 gerichtete antikörper mit bispezifischen formaten davon
|
|
CN121358771A
(zh)
|
2023-04-03 |
2026-01-16 |
非营利性组织佛兰芒综合大学生物技术研究所 |
血-脑屏障穿越抗体
|
|
WO2025014773A1
(en)
|
2023-07-07 |
2025-01-16 |
Viridian Therapeutics, Inc. |
Methods of treating chronic thyroid eye disease
|
|
AU2024299328A1
(en)
|
2023-07-21 |
2026-01-22 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025093683A1
(en)
|
2023-11-03 |
2025-05-08 |
Neuvasq Biotechnologies Sa |
Wnt7 signaling agonists
|
|
WO2025136985A1
(en)
|
2023-12-17 |
2025-06-26 |
Viridian Therapeutics, Inc. |
Compositions, doses, and methods for treatment of thyroid eye disease
|
|
WO2025151502A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Modified antibodies
|
|
WO2025151492A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025151496A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
US20260015407A1
(en)
|
2024-07-15 |
2026-01-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory fusion proteins and related methods
|